Human growth hormone produced with recombinant DNA technology: development and production

Acta Paediatr Scand Suppl. 1986;325:1-9. doi: 10.1111/j.1651-2227.1986.tb10356.x.


The molecular basis of recombinant DNA technology is described, and the principles of genetically engineered proteins developed. The production of hGH by such methods utilizes a strain of Escherichia coli as host and a vector plasmid containing the appropriate information. Fermentation and purification of the hGH produced gives a preparation of high purity, containing only 1-2 ppm of E. coli polypeptide (ECP). This somatrem (Somatonorm) is identical to pituitary hGH except for an additional methionine residue at the N-terminal. Monoclonal antibodies fail to distinguish between pituitary hGH and somatrem. Preclinical studies of a variety of pharmacological and toxicological parameters indicate that the two hGH preparations have identical biological effects; no toxicological or mutagenic effects of somatrem have been detected.

MeSH terms

  • Cloning, Molecular
  • DNA, Recombinant
  • Escherichia coli / genetics
  • Growth Hormone / analogs & derivatives*
  • Growth Hormone / biosynthesis
  • Growth Hormone / genetics
  • Growth Hormone / isolation & purification
  • Hormones / isolation & purification
  • Human Growth Hormone
  • Humans
  • Recombinant Proteins / biosynthesis*
  • Recombinant Proteins / genetics


  • DNA, Recombinant
  • Hormones
  • Recombinant Proteins
  • Human Growth Hormone
  • Growth Hormone